How did patients with relapsed or refractory multiple myeloma (RRMM) respond to treatment with XPOVIO® (selinexor) + dexamethasone?

    In the clinical trial, 122 adults with RRMM were treated with XPOVIO 80 mg + dexamethasone 20 mg on Days 1 and 3 of every week. The approval was based upon results in a subgroup of 83 patients who no longer responded to bortezomib, carfilzomib, lenalidomide, pomalidomide, and daratumumab.

    Clinical study results with XPOVIO + dexamethasone

    One in four patients icon One in four patients responded to treatment with XPOVIO + dexamethasone 1 in 4 patients One in four patients icon One in four patients

    1 in 4 patients

    responded to treatment
    with XPOVIO + dexamethasone

    Graphic showing median patient time to first response to XPOVIO® + dexamethasone Graphic showing median patient time to first response to XPOVIO® + dexamethasone

    In the clinical trial, patients took XPOVIO + dexamethasone for a median of 8 weeks, with some as long as 60 weeks.

    What is XPOVIO?

    XPOVIO® (selinexor) is a prescription medicine used:

    • in combination with dexamethasone to treat adults with multiple myeloma (MM) that has come back (relapsed) or that did not respond to previous treatment (refractory), and
      • who have received at least 4 prior therapies, and
      • whose disease did not respond (refractory) to at least 2 proteasome inhibitor medicines, at least 2 immunomodulatory agents, and an anti-CD38 monoclonal antibody medicine

    What is the most important information I should know about XPOVIO?

    Your healthcare provider will do blood tests before you start taking XPOVIO, and often during the first 3 months of treatment, and then as needed during treatment to monitor you for side ef‍fects. Your healthcare provider may change your dose of XPOVIO, stop your treatment for a period of time, or completely stop your treatment if you have certain side ef‍fects during treatment with XPOVIO.